Hagit Philip
Overview
Explore the profile of Hagit Philip including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
55
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cashman R, Haim-Abadi G, Lezmi E, Philip H, Nissenbaum J, Viner-Breuer R, et al.
Cell Prolif
. 2025 Jan;
e13788.
PMID: 39814695
Synthetic lethality is defined as a type of genetic interaction where the combination of two genetic events results in cell death, whereas each of them separately does not. Synthetic lethality...
2.
Nissenbaum J, Segal E, Philip H, Cashman R, Golan-Lev T, Reubinoff B, et al.
Cell Prolif
. 2024 Nov;
58(3):e13771.
PMID: 39523021
Taxanes and platinum molecules, specifically paclitaxel and carboplatin, are widely used anticancer drugs that induce cell death and serve as first-line chemotherapy for various cancer types. Despite the efficient effect...
3.
Segal E, Nissenbaum J, Peretz M, Golan-Lev T, Cashman R, Philip H, et al.
Cell Prolif
. 2023 Apr;
56(6):e13475.
PMID: 37086010
Anticancer drugs are at the frontline of cancer therapy. However, innate resistance to these drugs occurs in one-third to one-half of patients, exposing them to the side effects of these...
4.
Snir T, Philip H, Gordin M, Zilberberg A, Efroni S
Sci Data
. 2023 Feb;
10(1):108.
PMID: 36823176
Immunotherapy is now an essential tool for cancer treatment, and the unique features of an individual's T cell receptor repertoire are known to play a key role in its effectiveness....
5.
Philip H, Snir T, Gordin M, Shugay M, Zilberberg A, Efroni S
iScience
. 2021 Feb;
24(2):102100.
PMID: 33604527
Biology of the response to anti-CTLA-4 involves the dynamics of specific T cell clones. Reasons for clinical success and failure of this treatment are still largely unknown. Here, we quantified...
6.
Gordin M, Philip H, Zilberberg A, Gidoni M, Margalit R, Clouser C, et al.
PLoS Comput Biol
. 2021 Jan;
17(1):e1008486.
PMID: 33465095
The partial success of tumor immunotherapy induced by checkpoint blockade, which is not antigen-specific, suggests that the immune system of some patients contain antigen receptors able to specifically identify tumor...
7.
Cashman R, Zilberberg A, Priel A, Philip H, Varvak A, Jacob A, et al.
NPJ Precis Oncol
. 2020 May;
4:10.
PMID: 32352035
The introduction of novel cancer drugs and innovative treatments brings great hope for cancer patients, but also an urgent need to match drugs to suitable patients, since certain drugs that...
8.
Priel A, Gordin M, Philip H, Zilberberg A, Efroni S
Front Immunol
. 2019 Jan;
9:2913.
PMID: 30619277
The T cell repertoire potentially presents complexity compatible, or greater than, that of the human brain. T cell based immune response is involved with practically every part of human physiology,...
9.
Covacu R, Philip H, Jaronen M, Almeida J, Kenison J, Darko S, et al.
Cell Rep
. 2016 Mar;
14(11):2733-44.
PMID: 26972015
The T cell receptor (TCR) controls the cellular adaptive immune response to antigens, but our understanding of TCR repertoire diversity and response to challenge is still incomplete. For example, TCR...